Inventors:
Pamela Pavco - Lafayette CO, US
James McSwiggen - Boulder CO, US
Dan Stinchcomb - Ft. Collins CO, US
Jaime Escobedo - Alamo CA, US
Julian Kim - Shaker Heights OH, US
Daniel Lindner - Shaker Heights OH, US
Assignee:
Ribozyme Pharmaceuticals, Inc.
International Classification:
A61K048/00, C12N005/08
US Classification:
514/044000, 435/372000, 435/375000
Abstract:
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nuleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.